Novartis, “We have no plan to compensate for the difference of Galvusmet’s dropped price”
As the company announced it has no plan to compensate the difference of the decreased drug price of Galvusmet whose upper limit price will be dropped from the 1st of December, the distribution industry has made a strong opposition.
A company which jointly sell the Novartis’ DPP-4 inhibitor antid...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
